These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9595974)

  • 21. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis.
    Sorensen PS; Fazekas F; Lee M
    Eur J Neurol; 2002 Nov; 9(6):557-63. PubMed ID: 12453069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous immunoglobulin in MS: promise or failure?
    Fazekas F; Strasser-Fuchs S; Hommes OR
    J Neurol Sci; 2007 Aug; 259(1-2):61-6. PubMed ID: 17449063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulins in multiple sclerosis.
    Lisak RP
    Neurology; 1998 Dec; 51(6 Suppl 5):S25-9. PubMed ID: 9851727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.
    Sørensen PS; Wanscher B; Szpirt W; Jensen CV; Ravnborg M; Christiansen P; Schreiber K; Nordenbo A
    Neurology; 1996 Jun; 46(6):1620-5. PubMed ID: 8649560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis.
    Achiron A; Kishner I; Dolev M; Stern Y; Dulitzky M; Schiff E; Achiron R
    J Neurol; 2004 Sep; 251(9):1133-7. PubMed ID: 15372259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term safety of IVIg therapy in multiple sclerosis: 10 years experience.
    Katz U; Kishner I; Magalashvili D; Shoenfeld Y; Achiron A
    Autoimmunity; 2006 Sep; 39(6):513-7. PubMed ID: 17060031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma.
    Kishiyama JL; Valacer D; Cunningham-Rundles C; Sperber K; Richmond GW; Abramson S; Glovsky M; Stiehm R; Stocks J; Rosenberg L; Shames RS; Corn B; Shearer WT; Bacot B; DiMaio M; Tonetta S; Adelman DC
    Clin Immunol; 1999 May; 91(2):126-33. PubMed ID: 10227804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials.
    Sørensen PS
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):62-4. PubMed ID: 7964858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
    Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
    BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Austrian Immunoglobulin in MS (AIMS) study: final analysis.
    Strasser-Fuchs S; Fazekas F; Deisenhammer F; Nahler G; Mamoli B
    Mult Scler; 2000 Oct; 6 Suppl 2():S9-13. PubMed ID: 11188778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.
    Bech E; Lycke J; Gadeberg P; Hansen HJ; Malmeström C; Andersen O; Christensen T; Ekholm S; Haahr S; Höllsberg P; Bergström T; Svennerholm B; Jakobsen J
    Neurology; 2002 Jan; 58(1):31-6. PubMed ID: 11781402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.
    Dudesek A; Zettl UK
    J Neurol; 2006 Sep; 253 Suppl 5():V50-8. PubMed ID: 16998754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous Immunoglobulins in MS.
    Stangel M; Gold R
    Int MS J; 2005 Apr; 12(1):5-10, 4. PubMed ID: 15955273
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study.
    Achiron A; Rotstein Z; Noy S; Mashiach S; Dulitzky M; Achiron R
    J Neurol; 1996 Jan; 243(1):25-8. PubMed ID: 8869383
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL; Calabresi PA; Kieseier BC; Sheikh SI; Deykin A; Zhu Y; Liu S; You X; Sperling B; Hung S
    BMC Neurol; 2014 Dec; 14():240. PubMed ID: 25551571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intravenous immunoglobulins (IVIg) in the treatment of multiple sclerosis].
    Achiron A; Miron S
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S41-4. PubMed ID: 10896988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis -- outline of a double-blind randomized, placebo-controlled trial.
    Poehlau D; Federlein J; Postert T; Sailer M; Bethke F; Kappos L; Haas J; Przuntek H
    Mult Scler; 1997 Apr; 3(2):149-52. PubMed ID: 9291171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.